Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
Insmed is featuring its global Phase 3 PALM program for TPIP at CHEST 2026, with four pivotal studies spanning PAH, PH-ILD, PPF, and IPF. Three studies (PALM-PAH, PALM-ILD, PALM-PPF) are initiated, and PALM-IPF is expected to begin in the first half of 2027, with the program aiming to enroll more than 2,000 patients.
Key figures
- Drug Name
- TPIP (treprostinil palmitil inhalation powder)
- Phase Of Trial
- Phase 3
- Palm ipf start
- first half of 2027
- Pivotal studies
- 4
- Studies initiated
- PALM-PAH, PALM-ILD, PALM-PPF
- Planned enrollment
- more than 2,000 patients
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.